The Fibrinolytic System in Human Ascites

References

• White M J, Miller F N, Heuser L S, Pietsch CG. Human malignant ascites and histamin-induced protein leakage from the normal microcirculation. Microvasc Res 1988; 35: 63–72
   PubMed Web of Science ®Google Scholar
• Nagy J A, Herzberg K T, Dvorak J M, Dvorak HF. Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res 1993; 53: 2631–43
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Kimura M, Yamamoto T, Maeda H. Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn J Cancer Res 1988; 79: 1327–34
   PubMedGoogle Scholar
• Karlsrud T S, Bug L, Aasen A O, Johansen HT. Characterization of kininogens in human malignant ascites. Thromb Res 1991; 63: 641–50
   PubMed Web of Science ®Google Scholar
• Maeda H, Matsumura Y, Kato H. Purification and identification of (hydroxyprolyl3)bradykinin in ascitic fluid from a patient with gastric cancer. J Biol Chem 1988; 263: 16051–4
   PubMed Web of Science ®Google Scholar
• Buø L, Karlsrud T S, Johansen H T, Aasen AO. The contact system in human malignant and benign ascites. Scand J Clin Lab Invest 1993; 53: 117–24
   PubMed Web of Science ®Google Scholar
• Johansen H T, Bug L, Karlsrud T S, Aasen AO. Dextran sulphate activation of the Contact system in plasma and ascites. Thromb Res 1994; 76: 363–71
   PubMed Web of Science ®Google Scholar
• Oh D, Hwang S G, Hong S Y, Suh C I, Lee H B, Kye K C, et al. Fibrinolytic changes in malignant ascites. Fibrinolysis 1994; 8: 156–61
   Google Scholar
• Buø L, Lyberg T, Jørgensen L, Johansen H T, Aasen AO. Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas. APMlS 1993; 101: 2354
   Web of Science ®Google Scholar
• Buø L, Bjørnland K, Karlsrud T S, Kvale D, Kjønniksen I, Fodstad Ø, et al. Expression and release of plasminogen activators, their inhibitors, and receptor by human tumor cell lines. Anticancer Res 1994; 14: 2445–52
   PubMed Web of Science ®Google Scholar
• De Jong E, Knot E AR, Piket D, Burg AHC, Rijken D C, Veenhof K HN, et al. Increased plasminogen activator inhibition levels in malignancy. Thromb Haemost 1987; 57: 140–3
   PubMed Web of Science ®Google Scholar
• Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Semin Thromb Hemost 1987; 13: 50–68
   PubMed Web of Science ®Google Scholar
• Sprengers E D, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381–7
   PubMed Web of Science ®Google Scholar
• Vipond M N, Whawell S A, Thompson J N, Dudley H AF. Peritoneal fibrinolytic activity and intra-abdominal adhesions. Lancet 1990; 335: 1120–2
   PubMed Web of Science ®Google Scholar
• van Hinsbergh V WM, Kooistra T, Scheffer M A, van Bockel J H, van Muijen G NP. Characterization and fibrinolytic properties of human omental tissue mesothelial cells. Comparison with endothelial cells. Blood 1990; 75: 1490–7
   PubMed Web of Science ®Google Scholar
• Kingsley GR. The determination of serum total protein, albumin, and globulin by the biuret reaction. J Biol Chem 1939; 131: 197–200
   Google Scholar
• Aasen A O, Kierulf P, Strømme J. Methodological considerations on chromogenic peptide substrate assays and application on automated analyzers. Acta Chir Scand 1982; 509: 17–22, Suppl
   Google Scholar
• Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–5
   PubMed Web of Science ®Google Scholar
• Booth N A, Anderson J A, Bennett B. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. J Clin Pathol 1984; 37: 772–7
   PubMed Web of Science ®Google Scholar
• Granelli-Piperno A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223–34
   PubMed Web of Science ®Google Scholar
• Buø L, Karlsrud T S, Dyrhaug G, Jacobsen M B, Bell H, Johansen H T, et al. Differential diagnosis of human ascites: Inhibitors of the contact system and total proteins. Scand J Gastroenterol 1993; 28: 777–82
   PubMed Web of Science ®Google Scholar
• Galen R S, Gambino SR. Beyond normality: the predictive value and efficiency of medical diagnosis. John Wiley, New York 1975
   Google Scholar
• Conover WJ. Practical nonparametric statistics. Wiley, New York 1980; 288–90
   Google Scholar
• Patston P A, Gettins P GW, Schapira M. Serpins are suicide substrates: implications for the regulation of proteolytic pathways. Semin Thromb Hemost 1994; 20: 410–6
   PubMed Web of Science ®Google Scholar
• Rijken D C, Juhan-Vague I, Collen D. Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay. J Lab Clin Med 1983; 101: 285–94
   PubMed Web of Science ®Google Scholar
• Wun T-C, Capuano A. Initiation and regulation of fibrinolysis in human plasma at the plasminogen activator level. Blood 1987; 69: 1354–62
   PubMed Web of Science ®Google Scholar
• Testa J E, Quigley JP. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metast Rev 1990; 9: 353–67
   PubMed Web of Science ®Google Scholar
• Sier C FM, Fellbaum C, Verspaget H W, Schmitt M, Griffioen G, Graeff H, et al. Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. Histopathology 1991; 19: 231–7
   PubMed Web of Science ®Google Scholar
• Quax P HA, van Muijen G NP, Weening-Verhoeff E JD, Lund L R, Dana K, Ruiter DJ. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J Cell Biol 1991; 115: 191–9
   PubMed Web of Science ®Google Scholar
• Huber K, Wotja J, Kirchheimer J C, Ermler D, Binder BR. Plasminogen activators and plasminogen activator inhibitors in malignant and non-malignant ascitic fluid. Eur J Clin Invest 1988; 18: 595–9
   PubMed Web of Science ®Google Scholar
• Dörr P J, Brommer E IP, Dooijewaard G, Vemer HM. Peritoneal fluid and plasma fibrinolytic activity in women with pelvic inflammatory-disease. Thromb Haemost 1992; 68: 102–5
   PubMed Web of Science ®Google Scholar
• Casslén B, Ästedt B. The plasminogen activating system in ovarian carcinomas. Fibrinolysis 1992; 6: 65–9, Suppl 4
   Google Scholar
• Scott-Coombes D M, Whawell S A, Vipond M N, Crnojevic L, Thompson JN. Fibrinolytic activity of ascites caused by alcoholic cirrhosis and peritoneal malignancy. Gut 1993; 34: 1120–2
   PubMed Web of Science ®Google Scholar
• Dvorak H F, Senger D R, Dvorak AM. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metast Rev 1983; 2: 41–73
   PubMed Web of Science ®Google Scholar
• Nagy J A, Brown L F, Senger D R, Lanir N, van De Water L, Dvorak A M, et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1988; 948: 305–26
   Web of Science ®Google Scholar
• Kirchheimer J C, Huber K, Wagner O, Binder BR. Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas. Br J Haematol 1987; 66: 85–9
   PubMed Web of Science ®Google Scholar
• Purcell G, Phillips LL. Fibrinolytic activity in cirrhosis of the liver. Surg Gynecol Obstet 1963; 117: 1394
   Google Scholar
• Aoki N, Yamanaka T. The α2-plasmin inhibitor levels in liver diseases. Clin Chim Acta 1978; 84: 99–105
   PubMed Web of Science ®Google Scholar
• Tomb J. A cytopathological study on serous fluid in cancer. J Med Liban 1974; 27: 51–8
   PubMedGoogle Scholar
• Garrison R L, Kaelin L D, Heuser L S, Galloway RH. Malignant ascites: clinical and experimental observations. Ann Surg 1986; 203: 644–51
   PubMed Web of Science ®Google Scholar
• Runyon B A, Hoefs J C, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology 1988; 8: 1104–9
   PubMed Web of Science ®Google Scholar
• Runyon BA. Malignancy-related ascites and ascitic fluid ‘humoral tests of malignancy’. J Clin Gastroenterol 1994; 18: 94–8
   PubMed Web of Science ®Google Scholar
• Prieto M, Gomez-Lechon M J, Hoyos M, Castell J V, Carrasco D, Berenguer J. Diagnosis of malignant ascites: Comparison of ascitic fibronectin, cholesterol, and serum-ascites albumin difference. Dig Dis Sci 1988; 33: 833–8
   PubMed Web of Science ®Google Scholar
• Lu C-W, Wang S-S, Lee S-D, Tsai Y-T, Lee F-Y, Shiesh S-C, et al. Ascitic fluid analysis in peritoneal carcinomatosis: comparison of various biochemical tests with ascitic cirrhotics. Chin Med J 1991; 47: 350–6
   Google Scholar
• Adamsen S, Jönsson P, Brodin B, Lindberg B, Jorpes P. Measurement of fibronectin concentration in benign and malignant ascites. Eur J Surg 1991; 157: 325–8
   PubMedGoogle Scholar
• Siddiqui R A, Kochhar R, Singh V, Rajwanshi A, Goenka M K, Mehta SK. Evaluation of fibronectin as a marker of malignant ascites. J Gastroenterol Hepatol 1992; 7: 161–4
   PubMed Web of Science ®Google Scholar